Flualprazolam

From PsychonautWiki
Jump to navigation Jump to search

Skull and crossbones darktextred2.png

Fatal overdose may occur when benzodiazepines are combined with other depressants such as opiates, barbiturates, gabapentinoids, thienodiazepines, alcohol or other GABAergic substances.[1]

It is strongly discouraged to combine these substances, particularly in common to heavy doses.

Flualprazolam
Flualprazolam.png
Chemical Nomenclature
Common names Flualprazolam
Substitutive name Flualprazolam
Systematic name 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f] [1,2,4]triazolo[4,3-a] [1,4]diazepine
Class Membership
Psychoactive class Depressant
Chemical class Benzodiazepine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 50 - 100 µg
Light 0.1 - 0.3 mg
Common 0.3 - 0.5 mg
Strong 0.5 - 1 mg
Heavy 1 mg +
Duration
Total 5 - 8 hours
Onset 20 - 40 minutes
Peak 1 - 2 hours
Offset 2 - 6 hours
After effects 6 - 24 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


Flualprazolam is a novel depressant substance of the benzodiazepine class. It is a structural analog of alprazolam (Xanax), a widely used prescription benzodiazepine with high recreational potential. The mechanism is unknown, but it likely acts as a GABA receptor agonist.

Flualprazolam appears to have first become available for sale in 2017 on the online research chemical market.[2] The origins of its development is not clear. It has been marketed or deceptively sold as a replacement for alprazolam despite differing in substantive ways, according to some reports.

Subjective effects include sedation, muscle relaxation, disinhibition, anxiety suppression, memory suppression, and euphoria. Its effects are somewhat similar to alprazolam; however, it is reported to be more hypnotic and sedating than anxiolytic, and not as recreational. It appears to be more potent-by-weight than alprazolam.

Limited data exists on the pharmacological properties, metabolism, and toxicology of this compound. It likely possesses high abuse potential due to its similarity to alprazolam. The health risks of forming physical dependence to this compound are not known, and may possess additional risks relative to traditional benzodiazepines.

Additionally, it should be noted that the sudden discontinuation of benzodiazepines can be dangerous or even life-threatening for individuals for heavy or long-term users. As a result, individuals who are physically dependent on this substance are advised to taper their dose by gradually lowering the amount taken each day over a prolonged period instead of stopping use abruptly.[3]

Flualprazolam has been reported by users to dramatically and rapidly increase benzodiazepine cross-tolerance. It is strongly advised to only use Flualprazolam for short periods of time, and if used as an emergency substitute to avoid benzodiazepine withdrawal, to avoid compulsive redosing and minimize the administered dose as much as possible.

The potency of Flualprazolam compared to Alprazolam has been reported to vary dramatically by users (anywhere between 1.5x and 5x stronger than Alprazolam).

It is strongly advised to use harm reduction practices if using this substance.

History and culture

History icon.svg

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

Flualprazolam first appeared on the research chemical market around 2017[2]

Chemistry

Flualprazolam belongs to a class of synthetic organic compounds called benzodiazepines. Benzodiazepines contain a benzene ring fused to a diazepine ring, which is a seven membered ring with the two nitrogen constituents located at R1 and R4.

The benzyl ring of flualprazolam is substituted at R8 with a chlorine group. Further, the diazepine ring is bonded at R5 to a phenyl ring. The only difference to alprazolam is a fluorine group located at R2'.

Flualprazolam also contains a 1-methylated triazole ring fused to and incorporating R1 and R2 of its diazepine ring. Flualprazolam belongs to a class of benzodiazepines containing this fused triazole ring, called triazolobenzodiazepines, distinguished by the suffix "-zolam".

It can be described as the 2'-fluoro derivative of alprazolam, which it might share some of its effects[4], though some users report that it subjectively feels different than alprazolam in most aspects.

Pharmacology

Pill bottle-o.png

This pharmacology section is incomplete.

You can help by adding to it.

Flualprazolam can be described as the 2'-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.[5]

Subjective effects

Metacogghjgjvghnition.png
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Flualprazolam is reported to to be more hypnotic, have a longer duration, and a significantly longer elimination half-life than its parent compound alprazolam.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.


Physical effects
Child.svg

Cognitive effects
User.svg

Visual effects
Eye.svg

After effects
Aftereffects (3).svg

Paradoxical effects
Paradox placeholder.svg

Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.

Additional experience reports can be found here:

Toxicity and harm potential

Ambulance2.png

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Flualprazolam likely has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like alcohol or opioids.

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

Like most benzodiazepines, Flualprazolam is considered to be highly addictive with a high potential for abuse.

Tolerance will develop to the sedative-hypnotic effects within a couple of days of continuous use. After cessation, the tolerance returns to baseline in 7 - 14 days. However, in certain cases this may take significantly longer in a manner which is proportional to the duration and intensity of one's long-term usage.

Benzodiazepine discontinuation is notoriously difficult and potentially life-threatening for heavy or long-term users. There is an increased risk of seizure following discontinuation of benzodiazepines. Withdrawal symptoms or rebound symptoms may occur after ceasing usage abruptly following a few weeks or longer of steady dosing, and may necessitate a gradual dose reduction. Substances which lower the seizure threshold such as Tramadol should be avoided during withdrawal.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Stimulants - It can be dangerous to combine depressants with stimulants due to the risk of accidental excessive intoxication. Stimulants mask the sedative effect of depressants, which is the main factor most people use to gauge their level of intoxication. Once the stimulant effects wear off, the effects of the depressant will significantly increase, leading to intensified disinhibition, motor control loss, and dangerous black-out states. This combination can also potentially result in severe dehydration if one's fluid intake is not closely monitored. If choosing to combine these substances, one should strictly limit themselves to a pre-set schedule of dosing only a certain amount per hour until a maximum threshold has been reached.

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Internationally, Flualprazolam was added to the UN Convention on Psychotropic Substances as a Schedule II controlled substance in March 2020.[7][8]

  • Germany: Flualprazolam is controlled under Anlage II BtMG (Narcotics Act, Schedule II) [9] as of January 21, 2021.[10]
  • Turkey: Flualprazolam is a classed as drug and is illegal to possess, produce, supply, or import.[11]
  • United Kingdom: Flualprazolam is controlled under the Psychoactive Substances Act.[citation needed]
  • United States: Flualprazolam currently remains unscheduled.[citation needed]

See also

External links

References

  1. Risks of Combining Depressants (Tripsit) | https://tripsit.me/combining-depressants/
  2. 2.0 2.1 Flualprazolam - Google Trends | https://trends.google.com/trends/explore?date=all&geo=US&q=Flualprazolam
  3. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain - Appendix B-6: Benzodiazepine Tapering | http://nationalpaincentre.mcmaster.ca/opioid/cgop_b_app_b06.html
  4. Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S (May 2018). "The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines" (PDF).
  5. Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S (May 2018). "The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines" (PDF). Science & Justice. 58 (3): 219–225.
  6. Goyal, Sarita. "Drugs and Dreams." Indian Journal of Clinical Practice (n.d.): n. pag. Web. | http://medind.nic.in/iaa/t13/i3/iaat13i3p624.pdf
  7. "WHO: World Health Organization recommends 12 NPS for scheduling". December 2019. Retrieved October 16, 2020. 
  8. "CND accepts all WHO recommendations on the control of several psychoactive substances from the 42nd ECDD meeting". World Health Organization (WHO). March 18, 2020. Retrieved October 16, 2020. 
  9. "Anlage II BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved August 30, 2021. 
  10. "Einundzwanzigste Verordnung zur Änderung von Anlagen des Betäubungsmittelgesetzes". Bundesgesetzblatt Jahrgang 2021 Teil I Nr. 2 (in German). Bundesanzeiger Verlag. January 20, 2021. Retrieved August 30, 2021. 
  11. "Cumhurbaşkanı Kararı: Karar Sayısı: 1335" (PDF). Resmî Gazete, Sayı: 30837 (in Turkish). Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication] (published July 20, 2019). July 19, 2020.